enGene Therapeutics Inc. (ENGN NASDAQ) stock market data APIs
$2.4284
0(0%)
as of November 13, 2026
Try our APIs with
free plan!
enGene Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Prev. Close
2.4284
Open
2.4304
High
2.5312
Low
2.1806
52 wk Range
1.4-12.25
Market Cap
157 M
Shares Outstanding
67 016 K
EPS
0.47
Beta
-0.238
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get enGene Therapeutics Inc. data using free add-ons & libraries
Get enGene Therapeutics Inc. Fundamental Data
enGene Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -135 930 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get enGene Therapeutics Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-09-08
- EPS/Forecast: -0.44
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
enGene Therapeutics Inc. News
New
enGene Holdings GAAP EPS of -$0.47 misses by $0.04
* enGene Holdings press release [https://seekingalpha.com/pr/20642484-engene-reports-third-quarter-2026-financial-results-and-provides-business-update] (ENGN [https://seekingalpha.com/symbol/ENGN]):...
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical re...
EnGene Therapeutics Reports Wider Net Loss In Q2; Expects BLA Filing For Detalimogene In H2, 2026
(RTTNews) - enGene Therapeutics, Inc. (ENGN), a clinical-stage biotechnology company, reported results for the second quarter that ended on April 30, 2026, reflecting a wider net loss compared to the ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. (“Engene” or the “Company”) (NASDAQ: ENGN). Such invest...
Get enGene Therapeutics Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.